Expression of CD44 variant 9 in rectal cancer after treatment of neoadjuvant chemotradiotherapy

2016 Fiscal Year Final Research Report

• Project/Area Number: 26462004
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Digestive surgery
• Research Institution: University of Tsukuba
• Principal Investigator: Enomoto Tsuyoshi 筑波大学, 医学医療系, 講師 (10628762)
• Co-Investigator(Renkei-kenkyūsha): OHKOHCHI Nobuhiro 筑波大学, 医学医療系, 教授 (40213673) ; ODA Tatsuya 筑波大学, 医学医療系, 教授 (20282353) ; MURATA Soichiro 横浜市立大学, 大学院医学研究科, 准教授 (40436275) ; TAKEUCHI Tomoyo 筑波大学, 医学医療系, 助教 (50450333)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: 直腸癌 / 術前化学放射線療法 / CD44variant 9 / 癌幹細胞

Outline of Final Research Achievements

Introduction: CD44 variant 9 is important factor of cancer stem cell in colorectal cancer, however, its clinical role is uncertain.Aims: Objective of this study is to evaluate the immune-histochemical expression of CD44　variant 9 as stem cell marker in the colorectal cancer after treatment of neoadjuvant chemoradiotherapy (NCRT). Material and Methods: This study included 20 rectal specimens. All specimens were underwent NCRT. Clinical data were available for all case.Result: Average score of Expression of CD44 after NCRT is 0.93 (0-2.4). Expression score of CD44 variant 9 is in proportion to efficacy of pathological grade; grade2/ 1a/ 0 is 0.3/1.6/2, respectively. However, Expression score of relapse patient, non-relapse patient is 0.8 and 0.93, respectively. The correlation between relapse of tumor and expression of CD44 variant 9 is not significant.Conclusion: Expression of CD44 variant 9 might be associated with treatment effect of NCRT, however, no relation to prognosis.

Free Research Field

消化器外科学